The drug, which goes by the brand name Nucynta, is already approved for acute pain.
Tapentadol is a centrally acting synthetic analgesic. This oral mu-opioid agonist is taken twice daily in adults when a continuous, around-the-clock analgesic is needed over an extended time period.
Related Articles on FDA Device Approvals:
Technological Changes Affecting Eye ASCs: Q&A With Larry Patterson of Eye Centers of Tennessee
French Diagnostics Company Receives FDA Approval for MRSA Test
FDA Approves Solesta to Treat Life-Altering Fecal Incontinence
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
